MNPR Stock — Monopar Therapeutics Inc

Monopar Therapeutics Inc (MNPR)

Updated October 16, 2026.

MNPR is a Stock. Total return is -47.7% over the past 6.8 years, 210.6 points behind SPY at 162.9%.

Monopar Therapeutics is a clinical-stage biopharmaceutical company developing cancer treatments, including ALXN1840 for Wilson disease and MNPR-101, a monoclonal antibody-based radiotherapeutic and imaging agent for advanced solid tumors. The company does not currently distribute to shareholders. Monopar appeals to investors seeking exposure to early-stage drug development with potential for substantial gains if clinical trials succeed, though such investments carry significant risk of total loss.

MNPR performance versus SPY

Price and return data through 2026-10-16.

Total return is -47.7% over the past 6.8 years, 210.6 points behind SPY at 162.9%. Over the past year its total return — price change plus distributions reinvested — is -16.1%. Its deepest 1-year drawdown was 46.0%.

MNPR key facts

Asset type

Stock

Asset class

Equity

Inception date

12/19/2019

Distribution frequency

None

Last close

$69.27 (as of 2026-10-16)

Market cap

$464,952,154

Average volume

142398.0

Beta

1.513

Payout ratio

0.0%

EPS

$-2.20

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

MNPR risks and drawbacks

Total return has trailed SPY over the available window. The deepest 1-year drawdown on record here is 46.0%.

Who may consider MNPR — and who may not

It is a weaker fit for investors who need monthly cash flow (MNPR does not currently distribute); investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.

More on MNPR

• All tickers starting with M

Tagged: Healthcare.

Frequently asked questions